These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17827956)

  • 1. Hepatitis C virus with normal transaminase levels.
    Puoti C
    Dig Dis; 2007; 25(3):277-8. PubMed ID: 17827956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
    Dusheiko G; Danta M
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):130-1. PubMed ID: 16265150
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
    Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
    J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
    Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment.
    Derbala MF; Amer AM; Almohanadi M; John A; Amin A; John A; Sharma M; Alkaabi SR; Al Dweik NZ; Pasic F; Yaqoob R; Butt MT; Shebl FM
    J Viral Hepat; 2011 Jul; 18(7):e258-62. PubMed ID: 21108700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma.
    Puoti C; Guarisco R; Spilabotti L; Bellis L; Mitidieri Costanza O; Dell' Unto O; Elmo MG
    J Viral Hepat; 2012 Apr; 19(4):229-35. PubMed ID: 22404720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels.
    Brillanti S; Levantesi F; Nigro G; Vicari S; Roda E
    Ann Intern Med; 2003 Dec; 139(11):W83. PubMed ID: 14644911
    [No Abstract]   [Full Text] [Related]  

  • 10. [New trend in treatment in patients with chronic hepatitis C].
    Werling K; Tulassay Z
    Orv Hetil; 2006 Apr; 147(14):637-41. PubMed ID: 16711370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
    Deuffic-Burban S; Babany G; Lonjon-Domanec I; Deltenre P; Canva-Delcambre V; Dharancy S; Louvet A; Roudot-Thoraval F; Mathurin P
    Hepatology; 2009 Nov; 50(5):1351-9. PubMed ID: 19676130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical approach to the patient with chronic hepatitis C infection and normal aminotransferases.
    Zapata R
    Ann Hepatol; 2010; 9 Suppl():72-9. PubMed ID: 20714000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
    Hornberger J; Farci P; Prati D; Zeuzem S; Green J; Patel KK
    J Viral Hepat; 2006 Jun; 13(6):377-86. PubMed ID: 16842440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.
    Zeuzem S; Alberti A; Rosenberg W; Marcellin P; Diago M; Negro F; Prati D; Puoti C; Roberts SK; Shiffman ML
    Aliment Pharmacol Ther; 2006 Oct; 24(8):1133-49. PubMed ID: 17014573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.
    Kim TY
    Korean J Hepatol; 2012 Mar; 18(1):29-31. PubMed ID: 22511900
    [No Abstract]   [Full Text] [Related]  

  • 16. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
    Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
    Bini EJ; Mehandru S
    Aliment Pharmacol Ther; 2006 Mar; 23(6):777-85. PubMed ID: 16556180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Eliminating the gray zone. What can be done in normal ALT values?].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():75. PubMed ID: 15373059
    [No Abstract]   [Full Text] [Related]  

  • 19. Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C.
    Kronenberger B; Zeuzem S; Sarrazin C; Mihm U; von Wagner M; Hofmann WP; Piiper A; Herrmann E
    Antivir Ther; 2007; 12(5):779-87. PubMed ID: 17713161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
    Prati D; Shiffman ML; Diago M; Gane E; Rajender Reddy K; Pockros P; Farci P; O'Brien CB; Lardelli P; Blotner S; Zeuzem S
    J Hepatol; 2006 Apr; 44(4):679-85. PubMed ID: 16487620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.